



U.S. Department of Justice
Federal Bureau of Prisons

Health Services Division

Washington, D.C. 20534

March 31, 2022

MEMORANDUM FOR ALL CLINICAL DIRECTORS
ALL HEALTH SERVICE ADMINISTRATORS
ALL INSTITUTION CHIEF PHARMACISTS

FROM: (b)(6); (b)(7)(C) M.D., Medical Director
Health Services Division

SUBJECT: Clinical Guidance on Monoclonal Antibody Therapy
for COVID-19

The Health Services Division (HSD) recently updated the Clinical Guidance on Monoclonal Antibody Therapy for COVID-19, August 2021. The guidance is issued for immediate implementation throughout the Bureau of Prisons (BOP). It will soon be available on the Sallyport COVID-19 Resources page.

This update has been issued to reflect changes to the Emergency Use Authorization (EUA) of several monoclonal antibody therapies. The distribution of bamlanivimab and etesevimab are paused for distribution due to concerns with efficacy against SARS-CoV-2 variants. In addition to its indication for treatment of mild to moderate COVID-19 in patients at risk for severe illness, the FDA expanded the EUA for casirivimab and imdevimab to include use as post exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death. Institutions are reminded that casirivimab and imdevimab are available by request through the CFAD.

Thank you for your ongoing commitment to providing quality health care to the BOP inmate population. If you have any questions regarding these guidelines, please contact RADM (b)(6); (b)(7)(C) at (b)(6); (b)(7)(C)

cc: M. D. Smith, Assistant Director
RADM (b)(6); (b)(7)(C) PharmD, Sr. Deputy Assistant Director
(b)(6); (b)(7)(C) M.D., Medical Director
(b)(6); (b)(7)(C) D.O., Medical Director
Regional Medical Directors
Regional Health Services Administrators
Medical Asset Support Team Members
Regional Hepatitis Clinical Pharmacist Consultants
Regional HIV Clinical Pharmacist Consultants

HSD Branch Chiefs

HSD Chief Professional Officers

RADM (b)(6);(b)(7)(C) PharmD, Chief, Clinical Pharmacy Program